As well as recommending that selective COX-2 inhibitors only be an option for patients with arthritis who are at high risk of an adverse GI event, NICE also estimated that switching high-risk arthritis patients to selective COX-2 inhibitors would lead to an annual incremental expenditure of approximately £25 million to the National Health Service (NHS) [5]. This evidence concerns the gene PTGS2 and Arthritis.